UroAlert - GU Oncology Weekly

July 17, 2025

Videos

Peer-to-Peer Clinical Conversations

Optimizing Nadofaragene Firadenovec Patient Selection for BCG-Unresponsive Bladder Cancer: A Case-based Discussion - Patrick Hensley

Patrick Hensley

Patrick Hensley discusses optimizing patient selection and treatment timing for nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.

Real-World VA Study Shows on Use of ARPIs in Metastatic Hormone-Sensitive Prostate Cancer - Martin Schoen

Martin Schoen

Oliver Sartor interviews Martin Schoen to discuss his study of metastatic hormone-sensitive prostate cancer treatment patterns in veterans from 2013-2022.

Beyond the Abstracts

Multivariate Analysis of the Parameters Affecting the Choice of Surgical Treatment for Patients with Localized Renal Cell Carcinoma (RCC) - Beyond the Abstract

Identification of a 5-Gene Signature Panel for the Prediction of Prostate Cancer Progression - Beyond the Abstract

Conference Coverage

AUA 2025: Prespecified Third Interim Analysis of the Darolutamide Observational (DAROL) Study in Patients with nmCRPC: North American Subgroup Analysis

AUA 2025: Bladder Cancer Incidence and Plastics-Processing Waste Release in Ohio: Are Microplastics a Novel Risk Factor?

AUA 2025: Should I Use ctDNA to Guide Treatment Decisions Regarding Adjuvant Chemotherapy or IO Therapy after Radical Cystectomy?

AUA 2025: The Role of PSMA-Radioguided Surgery in Identifying Tumor Locatino and Local Staging in Prostate Cancer Patients Undergoing Radical Prostatectomy And Extended Lymph Node Dissection. Interim Analysis of Phase 2 Study

AUA 2025: Renal Mass Biopsy for Small Renal Masses: A Single Center 20-Year Experience

Physician-Scientist Review Articles

The Molecular Features and Spatial Architecture of Bladder Ewing Sarcoma - Expert Commentary

New PET Imaging Tracers and Targets for the Staging Biochemically Recurrent Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Circulating Tumor DNA Assay in Non-Muscle-Invasive Bladder Cancer - Expert Commentary

Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer.

MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial carcinoma of the urinary bladder.

Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant therapy.

Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial Study.

Expression Profiles of Co-Inhibitory Receptors in Non-Urothelial Bladder Cancer: Preclinical Evidence for the Next Generation of Immune Checkpoint Inhibitors.

Intravesical chemotherapy combination treatments for BCG-unresponsive nonmuscle invasive bladder cancer.

Prognostic Value of PLR, SIRI, PIV, SII, and NLR in Non-Muscle Invasive Bladder Cancer: Can Inflammatory Factors Influence Pathogenesis and Outcomes?

Development and Utilization of a Novel EHR-Based Care Pathway for Non-muscle Invasive Bladder Cancer.

An evidence gap map of the personalized medicine in bladder cancer.

Long-term trends in bladder cancer incidence using a harmonized staging variable - A SEER-based study.

Novel Strategies and Therapeutic Advances for Bladder Cancer.

Does Age-Related Immune Impairment Reduce BCG Treatment Response in Non-Muscle Invasive Bladder Cancer? - Expert Commentary

Novel Molecular Biomarkers to Guide Treatment Decision-Making in Metastatic Urothelial Cancer-a Patient Cohort Analysis - Beyond the Abstract

Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review.

Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer.

Penile & Urethral Cancers

Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Marker of HPV-Independent Disease.

Penile Cancer Profile in a Central European Context: Clinical Characteristics, Prognosis, and Outcomes-Insights from a Polish Tertiary Medical Center.

RNA-seq of penile squamous cell carcinoma shows ODC1 overexpression is associated with worse overall survival.

Renal Cancer

Genetic Insights Into Nephrolithiasis and Renal Cancer Predisposition: Precision Medicine in Genes, Diagnosis, and Therapy.

Survival benefits of Cytoreductive Nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study.

Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.

Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions.

Prevalence of Germline Variants in Advanced Renal Cell Carcinoma in North India.

Predicting hemorrhagic complications in robotic-assisted partial nephrectomy for renal tumors: simplifying risk assessment with tumor diameter and depth.

The Effect of Valvulopathy on Adverse In-Hospital Outcomes After Partial and Radical Nephrectomy.

Impact of 3D Reconstruction and Printing on Surgical Outcomes in Renal Tumour Surgery.

Thermal Ablation Modalities that Best Compete with Partial Nephrectomy for T1A and T1B Renal Cell Carcinoma: A Network Meta-Analysis.

Successful Management of Immune-Mediated Myelitis in a Renal Cancer Patient: A Case Report.

Prostate Cancer

CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors.

Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.

Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CT.

Robotic Stereotactic Body Radiation Therapy for High-Risk Prostate Cancer: The Georgetown University Experience.

Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.

Biochemical Recurrence in Pathologic T3-4 Prostate Cancer: Indications for Adjuvant Radiotherapy.

Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening.

How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective.

PSA/testosterone ratio as a potential biomarker to identify early progressors of adaptive therapy in metastatic castration sensitive prostate cancer.

Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023).

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus.

The role of radiotherapy in pelvic nodal recurrence following definitive treatment for prostate cancer.

Impact of three-dimensional prostate models during robot-assisted radical prostatectomy on surgical margins and functional outcomes.

Interpretation of PSMA-PET Among Urologists: A Prospective Multicentric Evaluation.

A Multicenter Machine Learning-Based Predictive Model of Acute Toxicity in Prostate Cancer Patients Undergoing Salvage Radiotherapy (ICAROS Study).

Tumor Segmentation on PSMA PET/CT Predicts Survival in Biochemical Recurrence of Prostate Cancer: A Retrospective Study Using [68Ga]Ga-PSMA-11 and [18F]-PSMA-1007.

Phenotypic Plasticity and Androgen Receptor Bypass Drive Cross-Resistance to Apalutamide in Castration-Resistant Prostate Cancer Cell Models.

Is [177Lu]Lu-PSMA-617 Redefining Value in mCRPC Care? A Meta-Analysis of Clinical and Economic Endpoints.

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.

Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence After Prostatectomy: STARR (NCT05455736): An Early Analysis from the STARR Trial.

Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis.

Treatment of biochemical recurrence after primary therapy with curative intent.

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Acute toxicity of SBRT in localized prostate cancer: A Spanish multicenter study.

Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience.

Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer.

Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.

Radioguided Surgery for Prostate Cancer - Beyond the Abstract

Optimizing Biopsy Decisions in PI-RADS 3 Lesions: Cross-Institutional Validation of a Local Clinical Risk Model - Beyond the Abstract

Upper Tract Tumors

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.

The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma.

Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma - Beyond the Abstract

BCG Response and Oncological Outcomes in High Risk Nonmuscle Invasive Bladder Cancer Following Previously Treated Upper Tract Urothelial Carcinoma: A Propensity-Matched Analysis - Beyond the Abstract

Testicular Cancer

Subinguinal Orchidectomy for Testicular Cancer: Innovation or Unnecessary Advancement.

Clinical experience and outcomes of post chemotherapy midline extraperitoneal approach to retroperitoneal lymph node dissection.

A study of subjective memory impairment in long-term testicular cancer survivors.

Robotic Retroperitoneal Lymph-Node Dissection for Testicular Cancer: Initial Experience - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC